Combined chemohormonal therapy for locally advanced prostate cancer offers extended control of PSA levels

Cancer News

Combined chemohormonal therapy for locally advanced prostate cancer offers extended control of PSA levels
ChemotherapyHormoneProstate
  • 📰 NewsMedical
  • ⏱ Reading Time:
  • 50 sec. here
  • 18 min. at publisher
  • 📊 Quality Score:
  • News: 79%
  • Publisher: 71%

For patients with locally advanced prostate cancer, combined treatment with chemotherapy and hormonal therapy offers extended control of prostate-specific antigen (PSA) levels, compared to hormonal therapy alone, reports a study in the April issue of The Journal of Urology, an Official Journal of the American Urological Association.

Apr 17 2024Wolters Kluwer For patients with locally advanced prostate cancer , combined treatment with chemotherapy and hormonal therapy offers extended control of prostate-specific antigen levels, compared to hormonal therapy alone, reports a study in the April issue of The Journal of Urology ®, an Official Journal of the American Urological Association . The journal is published in the Lippincott portfolio by Wolters Kluwer.

In a 2:1 ratio, patients were randomly assigned to treatment with the chemotherapy agent docetaxel plus hormonal therapy or hormonal therapy alone. In both groups, these "neoadjuvant" treatments were followed by surgery . Addition of chemotherapy prolongs time to rising PSA levels Both groups had good pathologic responses: the cancer was "downstaged" before surgery in 65% of patients assigned to chemohormonal therapy and 48% of with hormonal therapy only. The two groups also had similar rates of minimal residual disease – only a small number of cancer cells remaining after treatment.

Median time to rising PSA levels was 17 months with chemohormonal therapy versus 14 months with hormonal therapy alone. Patients receiving chemotherapy also had a higher treatment-free survival rate: 8.5% required no further prostate cancer treatment through five years' follow-up. The two groups had similarly low complication and adverse event rates.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

NewsMedical /  🏆 19. in UK

Chemotherapy Hormone Prostate Prostate Cancer Antigen Clinical Trial Docetaxel Healthcare Hormonal Therapy Prostatectomy Prostate-Specific Antigen Radical Prostatectomy Surgery Technology Tumor Urology

United States Latest News, United States Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

England 6-5 Brazil: Injuries benefit Pickford, Guimaraes as Real Madrid trio make combined XIEngland 6-5 Brazil: Injuries benefit Pickford, Guimaraes as Real Madrid trio make combined XIUsing players from both current squads, we have made a combined XI for Gareth Southgate's England and five-time World Cup winners Brazil.
Read more »

Tees Valley Combined Authority employs both daughters of its chief Julie GilhespieTees Valley Combined Authority employs both daughters of its chief Julie GilhespieBoth daughters of Tees Valley Combined Authority’s (TVCA) chief executive, Julie Gilhespie, have been employed by the combined authority, The Yorkshire Post can reveal.
Read more »

Gang who peddled 'high-purity cocaine' jailed for combined 46 yearsGang who peddled 'high-purity cocaine' jailed for combined 46 yearsA county lines organised crime gang peddling Class A drugs into Shropshire have been handed jail sentences of a combined 46 years.
Read more »

Two £1m 1881 Watford homes could combined into onePlans to knock through the walls and combine two Watford homes worth more than £1millon have been submitted.
Read more »

Combined scanning technique could refine treatment for early-stage breast cancer patientsCombined scanning technique could refine treatment for early-stage breast cancer patientsUsing a combined scanning technique on patients with early-stage breast cancer improved treatment in almost three out of ten cases in a trial presented at the 14th European Breast Cancer Conference today.
Read more »

A combined PET-MRI scan could improve treatment for patients with early breast cancerA combined PET-MRI scan could improve treatment for patients with early breast cancerUsing a combined scanning technique on patients with early-stage breast cancer improved treatment in almost three out of ten cases in a trial presented at the 14th European Breast Cancer Conference.
Read more »



Render Time: 2025-02-25 20:39:08